Lessening Organ dysfunction with VITamin C (LOVIT): protocol for a randomized controlled trial
Authors:
- on behalf of the Canadian Critical Care Trials GroupOGon behalf of the Canadian Critical Care Trials Group
- Marie-Hélène MasseMMMarie-Hélène Masse
- Julie MénardJMJulie Ménard
- Sheila SpragueSSSheila Sprague
- Marie-Claude BattistaMBMarie-Claude Battista
- Deborah J. CookDCDeborah J. Cook
- Gordon H. GuyattGordon H. Guyatt
- Daren K. HeylandDaren K. Heyland
- Salmaan KanjiSKSalmaan Kanji
- Ruxandra PintoRPRuxandra Pinto
- Andrew G. DayADAndrew G. Day
- Dian CohenDCDian Cohen
Open Access
- 8 January 2020
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-12
Abstract
Background: Sepsis is a health problem of global importance; treatments focus on controlling infection and supporting failing organs. Recent clinical research suggests that intravenous vitamin C may decrease mortality in sepsis. We have designed a randomized controlled trial (RCT) to ascertain the effect of vitamin C on the composite endpoint of death or persistent organ dysfunction at 28 days in patients with sepsis. Methods: LOVIT (Lessening Organ dysfunction with VITamin C) is a multicenter, parallel-group, blinded (participants, clinicians, study personnel, Steering Committee members, data analysts), superiority RCT (minimum n = 800). Eligible patients have sepsis as the diagnosis for admission to the intensive care unit (ICU) and are receiving vasopressors. Those admitted to the ICU for more than 24 h are excluded. Eligible patients are randomized to high-dose intravenous vitamin C (50 mg/kg every 6 h for 96 h) or placebo. The primary outcome is a composite of death or persistent organ dysfunction (need for vasopressors, invasive mechanical ventilation, or new and persisting renal replacement therapy) at day 28. Secondary outcomes include persistent organ dysfunction-free days to day 28, mortality and health-related quality of life at 6 months, biomarkers of dysoxia, inflammation, infection, endothelial function, and adverse effects (hemolysis, acute kidney injury, and hypoglycemia). Six subgroup analyses are planned. Discussion: This RCT will provide evidence of the effect of high-dose intravenous vitamin C on patient-important outcomes in patients with sepsis. Trial registration: clinicaltrials.gov, NCT03680274, first posted 21 September 2018.Keywords
Funding Information
- Lotte and John Hecht Memorial Foundation (4318)
This publication has 44 references indexed in Scilit:
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trialsCritical Care, 2011
- Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malariaProceedings of the National Academy of Sciences, 2008
- Serious adverse events in academic critical care researchCanadian Medical Association Journal, 2008
- A global clinical measure of fitness and frailty in elderly peopleCanadian Medical Association Journal, 2005
- Committee for proprietary medicinal products (CPMP) points to consider on adjustment for baseline covariatesStatistics in Medicine, 2004
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994
- APACHE IICritical Care Medicine, 1985
- Ascorbic Acid-Induced Hemolysis in G-6-PD DeficiencyAnnals of Internal Medicine, 1975